Open Access

Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study

  • Isis T da Silva1,
  • Anelise de Souza Timm1 and
  • Nágila RT Damasceno1, 2Email author
Lipids in Health and Disease201312:19

DOI: 10.1186/1476-511X-12-19

Received: 3 July 2012

Accepted: 4 December 2012

Published: 15 February 2013

Abstract

Background

Lipoprotein-associated phospholipase A2 activity (Lp-PLA2) is a good marker of cardiovascular risk in adults. It is strongly associated with stroke and many others cardiovascular events. Despite this, the impact of obesity on this enzyme activity and its relation to biomarkers of cardiovascular disease in adolescents is not very well investigated. The purpose of this article is to evaluate the influence of obesity and cardiometabolic markers on Lp-PLA2 activity in adolescents.

Results

This cross-sectional study included 242 adolescents (10–19 years) of both gender. These subjects were classified in Healthy Weight (n = 77), Overweight (n = 82) and Obese (n = 83) groups. Lipid profile, glucose, insulin, HDL size, LDL(−) and anti-LDL(−) antibodies were analyzed. The Lp-PLA2 activity was determined by a colorimetric commercial kit. Body mass index (BMI), waist circumference and body composition were monitored. Food intake was evaluated using three 24-hour diet recalls. The Lp-PLA2 activity changed in function to high BMI, waist circumference and fat mass percentage. It was also positively associated with HOMA-IR, glucose, insulin and almost all variables of lipid profile. Furthermore, it was negatively related to Apo AI (β = −0.137; P = 0.038) and strongly positively associated with Apo B (β = 0.293; P < 0.001) and with Apo B/Apo AI ratio (β = 0.343; P < 0.001). The better predictor model for enzyme activity, on multivariate analysis, included Apo B/Apo AI (β = 0.327; P < 0.001), HDL size (β = −0.326; P < 0.001), WC (β = 0.171; P = 0.006) and glucose (β = 0.119; P = 0.038). Logistic regression analysis demonstrated that changes in Apo B/Apo AI ratio were associated with a 73.5 times higher risk to elevated Lp-PLA2 activity.

Conclusions

Lp-PLA2 changes in function of obesity, and that it shows important associations with markers of cardiovascular risk, in particular with waist circumference, glucose, HDL size and Apo B/Apo AI ratio. These results suggest that Lp-PLA2 activity can be a cardiovascular biomarker in adolescence.

Keywords

Adolescent Lp-PLA2 Cardiovascular risk Obesity

Background

Obesity is developing very fast in all age groups, but the growth rate has been much more acute in children and adolescents [1]. According to the National Center for Health Statistics (NCHS), obesity increased from 5% to 18.1% among adolescents between 1976–1980 and 2007–2008 [1]. This profile is consistent with the Brazilian Institute of Geographic and Statistic, which showed that overweight in Brazilian adolescents increased from 16.7% (2002–2003) to 21.5% (2008–2009) [2].

The metabolic imbalance in obesity supports inflammation, insulin resistance and oxidation [35]. In adolescents, these components favor the early occurrence of atherosclerosis [6] by the emergence of chronic diseases like diabetes and abnormal lipid levels [7, 8].

Previously Celik et al. (2009) proposed that the incidence of obesity in adolescence may perhaps to represent a first step to atherosclerosis in adults [9]. Many factors can be associated with cardiovascular diseases, and it is known that Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a possible emerging biomarker [10]. Lp-PLA2 is an enzyme produced by inflammatory cells [11], that circulates on plasma linked in high proportion with low density lipoprotein (LDL) (85%) and less proportion to high density lipoprotein (HDL) (15%) [12]. Afterward, it was observed that Lp-PLA2 has the ability to hydrolysis oxidized phospholipids, reducing their biological activity [13]. However, this event results on the formation of lysophosphatidylcoline and isoprotanes, inflammatory components that participate in the development of atherosclerotic plaque [14].

Furthermore, it has been observed that Lp-PLA2, in adults, has association with other cardiovascular risk markers, such as LDL-C and C-reactive protein [15, 16]. A recent review showed that Lp-PLA2 is related to cardiovascular events in adults, even after adjustment by Framingham risk score and C protein reactive [17]. Despite these results, the monitoring of Lp-PLA2 in children and adolescents is sparkly described in literature. In addition, it is not know if obesity is associated to change of Lp-PLA2 in adolescents. In this context, the aim of this article is to evaluate the influence of obesity and cardiometabolic markers on Lp-PLA2 activity in adolescents.

Methods

Study subjects

In a cross-sectional study, we evaluated boys and girls adolescents between ten and nineteen years old [18], selected from public schools (Sao Paulo, SP, Brazil). From five public schools, 2746 adolescents were enrolled in this study. This population was initially invited to participate in the nutritional screening (body mass index – BMI, weight/height2). After a preliminary nutritional status classification, all adolescents with overweight (n = 481), obesity (n = 135) and a randomized sub-sample of healthy weight (n = 756) adolescents were invited to the second phase of the study. A total of 261 adolescents completed all stage of data collection.

The exclusion criteria were smoking, the use of alcohol (≥ 30.0 mL of ethanol/day for boys and ≥ 15.0 mL of etanol/day for girls) [19], the use of lipid-lowering drugs, the presence of any acute disease, the participation in other protocols research and pregnancy or breastfeeding. After an examination of collected data, 19 subjects were excluded due to the use of lipid-lowering and anti-inflammatory drugs during the collection.

The adolescents included in this study were distributed into 3 groups: healthy weight (HW), overweight (OV), and obese (OB), according to the classification of BMI, proposed by Cole et al. [20, 21] for sex and age. The protocol study was approved by the Ethics Committee (School of Public Health, University of Sao Paulo) and followed the recommendations of the National Council for Health on Ethics in Research with Humans. All the parents of the adolescents signed an informed written consent.

Food Intake

The food intake was evaluated by three 24-hour diet recalls, collected on non consecutive days, including one weekend day. The first recall was conducted by a direct interview and the others by phone interview. Energy (kcal), carbohydrates (g), lipids (g), proteins (g), saturated fat acid (g), monounsaturated fat acid (g), polyunsaturated fat acid (g), oleic acid (g), linoleic acid (g), linolenic acid (g) and fiber (g) were measured through the software NutWin® [22]. These data were adjusted by energy [23, 24] and by intra-personal variability [25].

Clinical and biochemical assessments

Height and weight were determined by a stadiometer (AlturaExata, TBW Brazil, Sao Paulo, SP, Brazil) and by a digital scale (Control, Plenna, Sao Paulo, SP, Brazil), respectively. Waist circumference (WC) was measured using a 1 mm precision flexible and inelastic tape (TBW Brazil®, Sao Paulo, SP, Brazil). Body composition was evaluated by bioelectric bioympedance technique, using the instrument tetrapolar Biodynamics®, model 450 (TBW, São Paulo, Brazil). Sexual maturation was evaluated according to Marshall and Tanner [26] and Marshall [27]. The levels of total cholesterol (TC), HDL-cholesterol (HDL-C), and triglycerides (TG) were determined by standard methods (Labtest Diagnóstica, MG, Brazil). The LDL-cholesterol (LDL-C) levels were calculated by the Friedewald equation [28]. Similarly, TC/HDL-C, LDL-C/HDL-C, no-HDL-C and TG/HDL-C ratios were calculated. The apolipoproteins AI (Apo AI) and B (Apo B) were evaluated by commercial kits (RANDOX®, Co, Antrim, United Kingdom). The concentrations of HDL-C and LDL-C were normalized by Apo AI and B levels, respectively. Posteriorly, the HDL size was measured by Laser-Light-Scattering method established by Lima and Maranhão [29].

The glucose was determined by an enzymatic and colorimetric commercial kit (Glicose PAP Liquiform® - Labtest, MG, Brazil). For insulin levels, the radioimmunoassay was applied using the standard method (Human Insulin-Specific RIA Kit, Linco Research, St Charles, MO, USA). Following up, the insulin resistance was estimated by HOMA-IR index (homeostasis model assessment – insulin resistance), where: HOMA-IR = [fasting insulin level (μU/mL) × fasting glucose (mmol/L)] / 22.5 [30].

The electronegative low density lipoprotein LDL(−) was assessed by ELISA using monoclonal antibodies (MAb 1A3 and MAb 2C7), according to Damasceno et al.[31], while the autoantibodies against LDL(−) were evaluated by ELISA, according to Damasceno et al.[32].

Lp-PLA 2 activity in plasma was determined by an enzymatic PAF-Acetylhydrolase Assay kit (Cayman Chemical Company, USA). The analyses were performed in duplicate, with its results expressed in nmol/min/mL.

Statistical analysis

The statistical analyses were performed using the SPSS software, version 15.0. Following the evaluation of the data distribution by Kolmogorov-Smirnov test (P > 0.05), differences between groups were determined by ANOVA test (normally data) or Kruskal-Wallis and Mann–Whitney U-test (not normally distributed data). The χ2 test was used for comparison of categorical variables and results were expressed as relative frequencies (%). Initially, there were performed sexual maturation- and sex-specific analysis; nonetheless, the groups showed similar profiles. Therefore, these variables were not accepted as confounders. Univariated regression models were applied in order to determine the effect of anthropometric/body composition and lipid measures (as explanatory variables) on Lp-PLA2 activity (as dependent outcome). In order to explore the ability of the variables that showed association with Lp-PLA2, additive multivariated regression models were constructed using the following variables: BMI, WC,% fat mass, TC, LDL-C, TC/HDL-C, non-HDL-C, Apo AI, Apo B, Apo B/Apo AI, HDL size, insulin, glucose and HOMA. Results from regression models are showed as b-coefficients, R-squared values and P- value.

We have also performed the Odd Ratio (OR) using logistic regression. Regarding that there is no reference values previously established for Lp-PLA2, we proposed the highest quartile (Q4) of Lp-PLA2 activity (>15.9 nmol/min/mL) such as cutoff point. Statistical significance was established for P-value <0.05.

Results

Table 1 shows the characteristics of adolescents included in the study, according to BMI. The proportion of girls (HW = 51%, OV = 45% and OB = 52%) were statistically similar between groups (P = 0.321). While the overweight adolescents (13.3 ± 1.9 years) was younger than both obese and healthy weight adolescents (P = 0.006), the OB group was marked by high fat mass percentage (32.2 ± 6.9%) and elevated central obesity (98 ± 16.5 cm), confirming previous BMI classification. It is worth to emphasize that food intake was similar between the groups.
Table 1

Characteristic of adolescents and food intake, according to BMI

 

HW (n = 77)

OV (n = 82)

OB (n = 83)

P

Boys, n (%)

26 (35.7)

37 (52.6)

31 (44.4)

0.320

Girls, n (%)

51 (64.3)

45 (47.4)

52 (55.6)

 

Age, year

14.4 (2.2)

13.3 (1.9)*

14.2 (2.6)**

0.006

Sexual Maturation

   

0.710

Pre-pubertal

4 (5)

7 (9)

6 (7)

 

Pubertal

73 (95)

75 (92)

77 (93)

 

BMI, kg/m 2

20.3 (2.1)

25.0 (1.9)*

32.4 (5.9)*.**

<0.001

WC, cm

69 (5.8)

80.7 (5.7)*

98 (16.5)*.**

<0.001

Fat mass,%

19.4 (7.9)

24.5 (6.6)*

32.2 (6.9)*.**

<0.001

Lean mass,%

76.1 (13.9)

71.3 (9.8)*

67.0 (7.5)*.**

<0.001

Food intake

    

Energy, kcal

1522 (471)

1446 (438)

1563 (521)

0.620

Carbohydrates, g

211 (20)

212 (19)

207 (27)

0.706

Proteins, g

64 (11)

64 (10)

66 (15)

0.719

Fat, g

50 (8)

51 (6)

51 (7)

0.313

SFA, g

17.7 (3.1)

17.4 (2.8)

17.7 (3.3)

0.480

PUFA, g

8.5 (2.0)

9.2 (2.0)

9.0 (2.7)

0.213

MUFA, g

17.3 (2.8)

17.9 (2.8)

17.7 (3.3)

0.159

Oleic acid, g

9.2 (2.2)

9.9 (1.7)

10.7 (2.8)

0.050

Linoleic acid, g

3.9 (1.0)

4.2 (1.0)

4.0 (1.0)

0.142

Linolenic acid, g

0.4 (0.1)

0.5 (0.1)

0.4 (0.1)

0.079

Fiber, g

11.1 (2.8)

10.7 (2.3)

10.7 (2.8)

0.948

HW, healthy weight; OV, overweight; OB, obese; BMI, body mass index; WC, waist circumference; SFA, saturated fat acid; PUFA, polyunsaturated fat acid; MUFA, monounsaturated fat acid.

Continuous variables were described as mean (standard deviation).

Categorical variables were described as sample (n) and percentage (%).

*P < 0.05 vs HW group. **P < 0.05 vs OV group.

As to the lipid profile, HDL-C was lower in OV and OB groups in comparison to HW group (P = 0.027; P < 0.001, respectively), and TG was higher in OB group (P = 0.026). The TC/HDL-C and TG/HDL-C ratios confirmed this tendency, where obese adolescents showed higher values in relation to healthy weight adolescents (P = 0.015). Regarding the apolipoproteins, they were similar between groups, except for Apo AI and Apo B/Apo AI ratio, where the OB group showed lower (P = 0.001) and higher (P = 0.002) levels, respectively, than HW group (Table 2). The insulin levels and HOMA-IR were higher in OV (P = 0.002 and P = 0.011, respectively) and OB groups (P < 0.001; P < 0.001, respectively) than in HW group. The similar pattern was observed for LDL(−), where obese and overweight adolescents showed values statistically higher than HW group (P = 0.049; P = 0.017, respectively). An opposite profile was noted for anti-LDL(−) (P = 0.045; P = 0.010, respectively) (Table 2).
Table 2

Adolescent’s biochemical profile, according to BMI

 

HW (n = 77)

OV (n = 82)

OB (n = 83)

P

TC, mg/dL

143 (32.1)

140 (34.3)

142 (39.8)

0.864

LDL-C, mg/dL

86 (33.5)

85 (35.6)

89 (40.1)

0.800

HDL-C, mg/dL

42 (13.5)

37 (13.3)*

35 (12.6)*

<0.001

TG, mg/dL

75 (29.7)

87 (49.7)

91 (45.1)*

0.07

TG/HDL-C

1.90 (0.86)

2.69 (1.98)*

3.07 (2.24)*

0.001

TC/HDL-C

3.67 (1.39)

4.02 (1.72)

4.59 (2.16)*

0.021

LDL-C/HDL-C

1.81 (0.52)

1.90 (0.90)

1.79 (0.71)

0.051

Non HDL-C

100.9 (33.9)

102.6 (38.3)

107.1 (43.2)

0,575

Apo AI, mg/dL

120.9 (18.0)

113.7 (19.6)

109.1 (21.2)*

0.001

Apo B, mg/dL

62.8 (10.6)

65.2 (15.8)

65.2 (17.5)

0.533

Apo B/Apo AI

0.53 (0.12)

0.60 (0.15)

0.61 (0.16)*

0.003

LDL-C/ApoB

1.38 (0.4)

1.33 (0.48)

1.37 (0.53)

0.810

HDL-C/ApoA

0.35 (0.09)

0.33 (0.12)

0.32 (0.10)

0.122

LDL (−), mg/mL

8.9 (5)

10.8 (4.9)

10.5 (5.2) *

0.042

Anti LDL(−), mg/mL

8.5 (2.6)

7.5 (2.7)*

7.2 (3.0)*

0.010

HDL size, nm

10.8 (2.7)

10.8 (2.3)

10.9 (3.2)

0.638

Glucose, mg/dL

79.3 (12.8)

78.0 (12.5)

82.0 (13.2)

0.130

Insulin, uU/mL

15.3 (7.1)

19.8 (8.2)*

25.9 (14.5)*;**

<0.001

HOMA-IR

3.0 (1.5)

3.9 (2.0)*

5.3 (3.1)*;**

<0.001

HW, healthy weight; OV, overweight; OB, obese; BMI, Body Mass Index; WC, waist circumference, HOMA-IR, homeostasis model assessment of insulin resistance; TC, total cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein.

Results were described as mean (standard deviation). *P < 0.05 vs HW group. **P < 0.05 vs OV group.

The Figure 1 shows that Lp-PLA2 activity changed in function to obesity. The negative impact of obesity on Lp-PLA2 activity was reinforced by tertiles of waist circumference and fat mass percentage. Regarding this profile, correlations between Lp-PLA2 and % fat mass, WC and BMI in all groups were analyzed, but it weren’t statistically significant, excepted for % fat mass that was negatively related to Lp-PLA2 in the OV group (r = −0.238 p = 0.033).
https://static-content.springer.com/image/art%3A10.1186%2F1476-511X-12-19/MediaObjects/12944_2012_Article_842_Fig1_HTML.jpg
Figure 1

Lp-PLA 2 activity in adolescents according to BMI, tertiles of waist circumference and fat mass percentage. A: Lp-PLA2 activity stratified by BMI. B: Lp-PLA2 activity stratified by waist circumference tertiles. C: Lp-PLA2 activity stratified by fat mass percentage tertiles. *P = 0.001 vs HW group or vs Lower tertile. HW, healthy weight; OV, overweight; OB, obese; BMI, Body Mass Index; WC, waist circumference.

Table 3 shows the association between Lp-PLA2 activity and cardiometabolic parameters. Lp-PLA2 activity was positively associated with almost all variables of lipid profile, except HDL-C and TG with which there was not correlation. Besides, Lp-PLA2 was negatively related to Apo AI (β = −0.137; P = 0.038) and strongly positively associated with Apo B (β = 0.293; P < 0.001) and with Apo B/Apo AI ratio (β = 0.343; P < 0.001). Other evidences are the positive associations with insulin, HOMA-IR and glucose. The enzyme activity was also positively associated with BMI (β = 0.195; P = 0.003), WC (β = 0.270; P < 0.001), fat mass percentage (β = 0.186; P = 0.004). These significant associations explained 64.5% of variability of Lp-PLA2, while the non significant represented 4.1%.
Table 3

Univariated regression model between Lp-PLA 2 and cardiometabolic factors

 

Lp-PLA2

 

R2

P*

β

BMI, kg/m 2

0.038

0.003

0.195

WC, cm

0.073

0.000

0.270

Fat mass,%

0.034

0.004

0.186

TC, mg/dL

0.035

0.004

0.186

LDL-C, mg/dL

0.016

0.051

0.128

HDL-C, mg/dL

0.001

0.671

−0.028

TG, mg/dL

0.008

0.163

0.091

TG/HDL-C

0.007

0.199

0.084

LDL-C/HDL-C

0.010

0.121

0.121

TC/HDL-C

0.018

0.042

0.133

Non HDL-C

0.022

0.022

0.149

HDL-C/ApoAI

0.001

0.585

0.036

Apo AI, mg/dL

0.019

0.038

−0.137

Apo B, mg/dL

0.082

0.000

0.293

Apo B/Apo AI

0.118

0.000

0.343

LDL-C/ApoB

0.000

0.775

−0.019

LDL(−), mg/mL

0.001

0.706

0.025

Anti LDL(−), mg/mL

0.013

0.078

−0.115

HDL size , nm

0.085

0.000

−0.291

Insulin, uU/mL

0.039

0.002

0.198

Glucose, mg/dL

0.019

0.034

0.138

HOMA-IR

0.047

0.001

0.216

BMI, Body Mass Index; WC, waist circumference, HOMA-IR, homeostasis model assessment of insulin resistance; TC, total cholesterol; TG, triglycerides; LDL, low density lipoprotein; HDL, high density lipoprotein.

Variables in log form, except for percentages. *Significant level (P < 0.05).

Given the multiple associations obtained in the univariated test, we analyzed the better model of multivariable association in order to understand the Lp-PLA2 activity in adolescents. The better predictor model was featured by Apo B/Apo AI (β = 0.327; P < 0.001)

HDL size (β = −0.326; P < 0.001), WC (β = 0.171; P = 0.006) and glucose (β = 0.119; P = 0.038) (Table 4). This model explained 26.3% of variability of Lp-PLA2.
Table 4

Multivariable linear regressions between Lp-PLA 2 and cardiometabolic factors

 

Lp-PLA2

 

R2

P*

β

Model

0.263

  

Apo B/Apo AI

 

0.000

0.327

HDL size

 

0.000

−0.326

WC

 

0.006

0.171

Glucose

 

0.038

0.119

WC, waist circumference; HDL size; high density lipoprotein size.

Variables in log form.

*Significant level (P < 0.05).

Using logistic regression analysis, we were able to determine the impact of cardiovascular risk factors on Lp-PLA2 activity (Table 5). Compared to adolescents with lower Lp-PLA2 activity (<15.9), those with higher values (≥15.9) exhibited significant association with TC (OR 1.012, 95% CI = 1.004-1.020, P = 0.004), LDL-C (OR 1.012, 95% CI = 1.004-1.020, P = 0.003), HOMA-IR (OR 1.127, 95% CI = 1.010-1.258, P = 0.032), Apo B (OR 1.042, 95% CI = 1.020-1.064, P < 0.001), Apo B/Apo AI (OR 73.53, 95% CI = 8.627-626.665, P < 0.001). The change in Apo B/Apo AI ratio was related to a 73.5 times higher risk to have a high value of Lp-PLA2 (≥15.9).
Table 5

Odd Ratio for Lp-PLA 2 activity highest quartile

 

Lp-PLA2

 
 

<15.9

≥15.9

P*

TC, mg/dL

1 Ref

1.012

0.004

LDL-C, mg/dL

1 Ref

1.012

0.003

HDL-C, mg/dL

1 Ref

0.983

0.162

TG, mg/dL

1 Ref

1.004

0.178

HOMA-IR

1 Ref

1.127

0.032

HDL size, nm

1 Ref

0.930

0.245

LDL(−), mg/mL

1 Ref

1.000

0.757

Anti LDL(−), mg/mL

1 Ref

0.878

0.020

Apo AI mg/dL

1 Ref

0.993

0.374

Apo B mg/dL

1 Ref

1.042

0.000

Apo B/Apo AI

1 Ref

73.5

0.000

LDL-C/ApoB

1 Ref

1.265

0.443

HDL-C/ApoAI

1 Ref

0.123

0.168

BMI, kg/m 2

1 Ref

1.022

0.340

WC, cm

1 Ref

1.014

0.126

Fat mass,%

1 Ref

1.015

0.379

HW, healthy weight; OV, overweight; OB, obese; BMI, Body Mass Index; WC, waist circumference, HOMA-IR, homeostasis model assessment of insulin resistance; TC, total cholesterol, TG, triglycerides; LDL, low density lipoprotein; HDL, high density lipoprotein.

*Significant level (P < 0.05).

Discussion

This study showed that Lp-PLA2 activity in adolescence is associated with many cardimetabolic parameters. The factors that had an impact in the activity of the enzyme, from the most to the least important, were the Apo B/Apo AI ratio, waist circumference, glucose and HDL size.

Our results demonstrated the negative effect of obesity on Lp-PLA2 activity, which were reinforced by waist circumference and fat mass percentage. Among the anthropometric variables the waist circumference was the most important factor explaining the variation in the Lp-PLA2 activity. This fact confirms the relevance of the body fat location. Interestingly, analysis of correlations in individual groups did not show association with healthy weight and overweight adolescents, except for fat mass percentage and Lp-PLA2 activity. In this sense, Taylor and Hergenroeder demonstrated that elevated waist circumference in male adolescents was associated with an increased risk of cardiometabolic disease and overweight females with elevated waist circumference were likely to have elevated blood pressure [33].

In addition, we demonstrated for the first time the strong impact of Apo B/Apo AI ratio on changes in Lp-PLA2 activity; more specifically, the changes in these apolipoproteins were associated with a 73.5 times higher risk of elevated Lp-PLA2 activity. Recently, Hatoum et al.[34], studying patients between 50 and 60 years old, observed that the enzyme was modestly associated with total cholesterol, LDL-C, Apo B and BMI; however, the lipid adjustment attenuates the relation between BMI and Lp-PLA2. The atherogenic role of Lp-PLA2 was widely associated to LDL-C [16, 35]. On the contrary, Okamura et al.[16] suggested that Lp-PLA2 in HDL plays an antiaterogenic action. This observation was reinforced by a high LDL-Lp-PLA2 to HDL-Lp-PLA2 ratio verified in patients with atrial fibrillation. In the same way, Rizos et al.[12] and Lagos et al.[36] observed a high total Lp-PLA2 activity in patients with metabolic syndrome, however, HDL-Lp-PLA2 showed low activity. Accordingly, our results confirm the impact of HDL and LDL on Lp-PLA2 activity given the strong association of this enzyme with Apo B/Apo AI ratio, that was the most important parameter related to the risk of increasing of Lp-PLA2 activity in adolescents.

The negative association of Lp-PLA2 with HDL-size signals a possible scenario where the functionality of HDL particles is impaired. Accordingly, Pascot et al., [37] showed that the small HDL particle has been associated with atherogenic dyslipidemic profile and hyperinsulinemia. More recently, Medina-Urrutia et al.[38] demonstrated that adolescents with small HDL have reduced HDL-C, high triglycerides and HOMA-IR. Rizos et al.[12] verified that patients with metabolic syndrome have higher Lp-PLA2 than the control group, but the enzyme linked to HDL-Lp-PLA2 was lower in this group and negatively associated with HOMA-IR.

Tsimikas et al.[39], analyzing patients with or without cardiovascular events, observed that Lp-PLA2 was positively correlated with HOMA-IR in the two groups; nonetheless, the correlation was higher in the cardiovascular event group. In this fashion, our study demonstrated that this enzyme was positively correlated with glucose, reinforcing the notion of the negative impact of obesity on glucose metabolism.

Previous studies have shown that Lp-PLA2 is a good marker for cardiovascular risk in adults [10, 15, 40]. For instance, the Lp-PLA2 Studies Collaboration showed that the enzyme activity was positively correlated with non-HDL-C, LDL-C, Apo B and negatively correlated with HDL-C and Apo AI [10]. In the same way, Sabatine et al.[41] emphasized that Lp-PLA2 is an important predictor of coronary revascularization and unstable angina, and can also be treated as a new risk factor.

In contrast to many investigations related to negative impact of obesity on lipids, few studies including children and adolescents that linked obesity, lipid profile and Lp-PLA2. At the moment, there are only four studies evaluating Lp-PLA2 in children and adolescents. First, Okada et al.[42] showed that the Lp-PLA2 concentration of 17 obese children (11.9 ± 0.7 years old) was positively correlated with weight, waist/height ratio, subscapular/triceps ratio and LDL-C level. Castro et al.[43] compared diabetic young adults and adolescents (24.9 ± 7.8 years old) with controls (24.3 ± 9.6 years old), observing higher Lp-PLA2 activity and elevated susceptibility for oxidized LDL in diabetic patients. Subsequently, Nagel et al.[44], studying children with 10 years old, observed that overweight was positively associated with cardiometabolic markers, including Lp-PLA2 concentration. In 2011, Motykova et al. [45], examining a group of non-diabetic obese/overweight children, verified that body weight reduction determined a drop of Lp-PLA2 levels, but even after this alteration the concentrations remain elevated. Our study confirms the negative impact of Lp-PLA2 and amplifies these results in function of sample size, number cardiometabolic markers and the age of the adolescents included.

In addition, many studies have shown that Lp-PLA2 activity is elevated in hypercholesterolemic, diabetic and metabolic syndrome patients [12, 46]. Nambi et al.[47] associated C-reactive protein and Lp-PLA2 to traditional risk factors for cardiovascular disease and proposed that these variables can be especially useful in individuals that are in intermediate risk according to these evaluations. Hence, Lp-PLA2 appears to be an important link between oxidation, inflammation, and altered lipid profile and insulin resistance on cardiovascular diseases. This action maybe involves the formation of lysophosphatidylcholine and isoprostanes that are the bioactive lipids released by Lp-PLA2[14].

In spite of the important results obtained, we believe that this study shows limitations directly related to the design (cross-sectional) that limits the establishment of the causal impact of our results on prevalence of clinical events.

Finally, we conclude that in adolescence, Lp-PLA2 changes in function of obesity, and that it shows important associations with markers of cardiovascular risk, in particular with waist circumference, glucose, HDL size and Apo B/Apo AI ratio. This supports the hypothesis that Lp-PLA2 can be a biomarker of cardiovascular risk in adolescence, however for confirm this; new prospective cohorts will be required.

Abbreviations

Anti-LDL(−): 

Autoantibodies against electronegative low density lipoprotein

Apo AI: 

Apolipoprotein AI

Apo B: 

Apolipoprotein B

BMI: 

Body mass index

HDL: 

High density lipoprotein

HOMA-IR: 

Homeostasis model assessment – insulin resistance

HW: 

Healthy weight

LDL(−): 

Electronegative low density lipoprotein

Lp-PLA2

Lipoprotein-associated phospholipase A2

OB: 

Obese

OR: 

Odd Ratio

OV: 

Overweight

TG: 

Triglycerides

WC: 

Waist circumference.

Declarations

Acknowledgements

This study was supported by FAPESP (07/51664-5; 07/52123-8) and CNPQ (474112/07-1).

Authors’ Affiliations

(1)
Department of Nutrition, School of Public Health, University of Sao Paulo
(2)
Faculdade de Saúde Pública, Departamento de Nutrição

References

  1. Ogden, Cynthia, and Margaret Carroll: "Prevalence of obesity among children and adolescents: United States, trends 1963–1965 through 2007–2008.". 2010,http://www.cdc.gov/nchs/data/hestat/obesity_child_07_08/obesity_child_07_08.htm, Centers for Disease Control and Prevention. National Center for Health Statistics, Atlanta,
  2. IBGE: Antropometria e Análise do estado nutricional de crianças e adolescentes no Brasil. Pesquisa de orçamentos familiares, 2002–2003. 2006, http://www.ibge.gov.br/home/presidencia/noticias/noticia_visualiza.php?id_noticia=1699%26id_pagina=1 2010,
  3. Fiedman JM: Obesity in the new millennium. Nature. 2000, 404: 632-634.
  4. Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004, 25: 4-7. 10.1016/j.it.2003.10.013View ArticlePubMed
  5. Linna MS, Borg P, Kukkonen-Harjula K, Foglholm M, Nenonem A, Ahotupa M, Vasankari TJ: Successful weight maintenance preserves lower levels of oxidized LDL achieved by weight reduction in obese men. Int J Pediatr Obes. 2007, 31: 245-253. 10.1038/sj.ijo.0803413. 10.1038/sj.ijo.0803413View Article
  6. Holvoet P: Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg. 2008, 70: 193-219.PubMed
  7. SEARCH for Diabetes in Youth Study Group: The Burden of Diabetes Mellitus Among US Youth: Prevalence Estimates From the SEARCH for Diabetes in Youth Study. Pediatrics. 2006, 118: 1510-1518.View Article
  8. CDC(Center for Disease Control): Prevalence of Abnormal Lipid Levels among Youths — United States, 1999–2006. Weekly. 2010, 59: 29-64.
  9. Celik T, Iyisoy A, Yuksel UC, Isik E: The role of abdominal obesity and weight gain since adolescence in early atherosclerosis. Int J Cardiol. 2009, 132: 263-295. 10.1016/j.ijcard.2007.05.094View ArticlePubMed
  10. The Lp-PLA2 Studies Collaboration: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010, 375: 1536-1544.PubMed CentralView Article
  11. Karabina S, Ninio E: Plasma PAF-acetylhydrolase: An unfulfilled promise?. Biochim Biophys Acta. 2006, 1761: 1351-1358. 10.1016/j.bbalip.2006.05.008View ArticlePubMed
  12. Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M: Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2005, 72: 203-209. 10.1016/j.plefa.2004.10.021View ArticlePubMed
  13. Tselepis AD, Chapmam MJ: Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase. Atherosclerosis. 2002, 3: 57-68. 10.1016/S1567-5688(02)00045-4View ArticlePubMed
  14. Sánchez-Quesada JL, Benítez S, Ordóñez-Llanos J: Electronegative low-density lipoprotein. Curr Opin Lipidol. 2004, 15: 329-335. 10.1097/00041433-200406000-00014View ArticlePubMed
  15. Persson M, Nilsson J, Nelson J, Hedblad B, Berglund G: The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2007, 190: 388-396. 10.1016/j.atherosclerosis.2006.02.016View ArticlePubMed
  16. Okamura K, Miura S, Zhang B, Uehara Y, Matsuo K, Kumagai K, Saku K: Ratio of LDL- to HDL-Associated Platelet-Activating Factor Acetylhydrolase may be a Marker of Inflammation in Patients With Paroxysmal Atrial Fibrillation. Circ J. 2007, 71: 214-219. 10.1253/circj.71.214View ArticlePubMed
  17. Madjid M, Ali M, Willerson JT: Lipoprotein-Associated Phospholipase A2 as a Novel Risk Marker for Cardiovascular Disease. Tex Heart Inst J. 2010, 37: 25-39.PubMed CentralPubMed
  18. WHO (World Health Organization: Nutrition in adolescence Issues and Challenges for the Health Sector. 2005, WHO, Geneva.
  19. Sociedade Brasileira de Hipertensão: IV Diretrizes Brasileiras de Hipertensão Arterial. Arq Bras Cardiol. 2004, 82 (IV): 7-14.
  20. Cole T, Bellizze MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ. 2000, 320: 1-6. 10.1136/bmj.320.7226.1View Article
  21. Cole T, Flegal KM, Nicholls D, Jackson AA: Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ. 2007, 335: 1-9. 10.1136/bmj.39262.506528.47View Article
  22. UNIFESP - Nutrition Data System NDS®: Food and Nutrient Database version 35. 2005,http://www.unifesp.br/dis/produtos/nutwin/index.htm, Regent of the University of Minnesota.
  23. Willett W, Stampfer M: Implications of total energy intake for epidemiologic analysis. Nutritional epidemiology. 1998, Oxford University Press, New York, 2.
  24. Mackerras D: Energy adjustment the concepts underlying the debate. J Clin Epidemiol. 1996, 49: 957-962. 10.1016/0895-4356(96)00142-4View ArticlePubMed
  25. Nusser SM, Carriquiry AL, Dodd KW: A Semiparametric Transformation Approach to estimating Usual Daily Intake distributions. J Am Stat Assoc. 1996, 91: 1440-1449. 10.1080/01621459.1996.10476712. 10.1080/01621459.1996.10476712View Article
  26. Marshall WA: Variations in pattern of pubertal changes in girls. Arch Dis Childhood. 1969, 44: 291-303. 10.1136/adc.44.235.291. 10.1136/adc.44.235.291View Article
  27. Marshall WA, Tanner JM: Variations in pattern of pubertal changes in boys. Arch Dis Childhood. 1970, 44: 13-23.View Article
  28. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed
  29. Lima ES, Maranhão RC: Rapid, Simple Laser-Light-Scattering Method for HDL Particle Sizing in Whole Plasma. Clin Chem. 2004, 50 (6): 1086-1088. 10.1373/clinchem.2004.032383View ArticlePubMed
  30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in men. Diabetologia. 1985, 28: 412-419. 10.1007/BF00280883View ArticlePubMed
  31. Damasceno N, Sevanian A, Apolinário E, Oliveira J, Fernandes I, Abdalla D: Detection of electronegative low density lipoprotein (LDL) in plasma and atherosclerotic lesions by monoclonal antibody-based immunoassays. Clin Biochem. 2006, 39: 28-38. 10.1016/j.clinbiochem.2005.09.014View ArticlePubMed
  32. Damasceno NRT, Apolinario E, Fernandes I, Flauzino FD, Abdalla DSP: Soy isoflavones reduce electronegative low density lipoprotein (LDL-) and anti-LDL- autoantibodies in experimental atherosclerosis. Eur J Nutr. 2007, 46: 125-132. 10.1007/s00394-006-0640-9View Article
  33. Taylor SA, Hergenroeder AC: Waist circumference predicts increased cardiometabolic risk in normal weight adolescent males. Int J Pediatr Obes. 2012, 6: 307-311.View Article
  34. Hatoum IJ, Nelson JJ, Cook NR, Hu FB, Rimm EB: Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr. 2010, 91: 786-793. 10.3945/ajcn.2009.28870PubMed CentralView ArticlePubMed
  35. Tsimihodimos V, Karabina SP, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD: Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB. Arterioscler Thromb Vasc Biol. 2002, 22: 306-311. 10.1161/hq0202.102918View ArticlePubMed
  36. Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf MS: Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome. Lipids. 2008, 44: 9-16.View ArticlePubMed
  37. Pascot A, Lemieux I, Prud’homme D, Tremblay A, Nadeau A, Couillard C, Bergeron J, Lamarche B, Després JP: Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. Lipid Res. 2001, 42: 2007-2014.
  38. Medina-Urrutia A, Juarez-Rojas JG, Martínez-Alvarado R, Jorge-Galarza E, Posadas-Sánchez R, Cardoso-Saldaña G, Caracas-Portilla N, Mendoza-Perez E, Posadas-Romero C: High-density lipoprotein subclasses distribution and composition in Mexican adolescents with low HDL cholesterol and/or high triglyceride concentrations, and its association with insulin and c-reactive protein. Atherosclerosis. 2008, 201: 392-397. 10.1016/j.atherosclerosis.2008.02.029View ArticlePubMed
  39. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S: Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J. 2009, 30: 107-115.View ArticlePubMed
  40. Li N, Li S, Yu C, Gu S: Plasma Lp-PLA2 in acute coronary syndrome: association with major adverse cardiac events in a community-based cohort. Postgrad Med. 2010, 122: 200-205. 10.3810/pgm.2010.07.2187View ArticlePubMed
  41. Sabatine MS, Morrow DA, O’Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J: Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease. Arterioscler Thromb Vasc. 2007, 27: 2463-2469. 10.1161/ATVBAHA.107.151670. 10.1161/ATVBAHA.107.151670View Article
  42. Okada T, Miyashita M, Kuromori Y, Iwata F, Harada K, Hattori H: Platelet-Activating Factor Acetylhydrolase Concentration in Children With Abdominal Obesity. Arterioscler Thromb Vasc Biol. 2006, 26: 40-e41. 10.1161/01.ATV.0000217284.86123.2c. 10.1161/01.ATV.0000217284.86123.2cView Article
  43. Castro SH, Faria Neto HCC, Gomes MB: Platelet-Activating Factor Acetylhydrolase (PAF-AH) Activity in Patients with Type 1 Diabetes Mellitus. Arq Bras Cardiol. 2007, 88: 179-184. 10.1590/S0066-782X2007000200008View ArticlePubMed
  44. Nagel G, Rapp K, Wabitsch M, Buchele G, Kroke A, Zollner I, Weiland SK, Koenig W: Prevalence and Cluster of Cardiometabolic Biomarkers in Overweight and Obese Schoolchildren: Results from a Large Survey in Southwest Germany. Clin Chem. 2008, 54: 2317-2325.View Article
  45. Motykova E, Zlatohlavek L, Prusikova M, Lanska V, Ceska R, Vasickova L, Vrablik M: Lifestyle modification induced weight loss and changes of cardiometabolic risk factors including lowering of inflammatory response in obese children. Neuro Endocrinol Lett. 2011, 32 (Suppl 2): 55-59.PubMed
  46. Campo S, Sardo MA, Bitto A, Bonaiuto A, Trimarchi G, Bonaiuto M, Castaldo M, Saitta C, Cristadoro S, Saitta A: Platelet-Activating Factor Acetylhydrolase Is Not Associated with Carotid Intima-Media Thickness in Hypercholesterolemic Sicilian Individuals. Clin Chem. 2004, 50: 2077-2082. 10.1373/clinchem.2004.036863View ArticlePubMed
  47. Nambi V, Hoogeveen RC, Chambless L, Hu Y, Bang H, Coresh J, Ni H, Boerwinkle E, Mosley T, Sharrett R, Folsom AR, Ballantyne CM: Lipoprotein-Associated Phospholipase A2 and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 2009, 40: 376-381. 10.1161/STROKEAHA.107.513259PubMed CentralView ArticlePubMed

Copyright

© da Silva et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement